News
The drop comes the day after the drugmaker said it would add a so-called black-box warning to its gene therapy Elevidys after ...
Sarepta faces FDA scrutiny over Elevidys as analysts downgrade stock and warn of long-term debt risks amid market uncertainty ...
U.S. regulators asked Sarepta Therapeutics on Friday to voluntarily halt shipments of its Elevidys gene therapy after a ...
Arrowhead Pharmaceuticals has moved to reassure Wall Street about its deal with Sarepta Therapeutics, telling investors that ...
Sarepta Therapeutics' licensing partner Arrowhead Pharmaceuticals said on Wednesday it expects to receive near-term milestone ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT – Research Report) and Biogen (BIIB – Research Report). Elevate Yo ...
For Sarepta, the hits keep coming, with several downgrades in the past week after it was forced to temporarily take its ...
On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.
Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...
After initially refusing to suspend Elevidys distribution after two deaths, Sarepta has now given in to the FDA’s request, ...
As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head, the biotech is standing firm ...
Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results